Copyright
©2013 Baishideng Publishing Group Co.
World J Gastrointest Endosc. Apr 16, 2013; 5(4): 180-185
Published online Apr 16, 2013. doi: 10.4253/wjge.v5.i4.180
Published online Apr 16, 2013. doi: 10.4253/wjge.v5.i4.180
Agent | Mechanism |
Amphetamines | Vasoconstriction |
Alosetron | |
Catecholamines (epinephrine, norepinephrine) | |
Cocaine | |
Cyclosporine | |
Digitalis | |
Dopamine | |
Ergot derivatives | |
Nonsteriodal anti-inflammatory drugs | |
Pseudoephedrine | |
Triptans (Naratriptan, Rizatriptan, Sumatriptan) | |
Vasopressin and vasopressin analogues | |
Glycerin enema | Local vasospasm effect |
Phosphosoda solution | |
Angiotensin-converting enzyme inhibitors | Systemic hypotension |
Antipsychotic (chlorpromazine) | |
Beta blockers | |
Barbiturates | |
Diuretics | |
Interleukin-2 | |
Tricyclic antidepressants | |
Amphetamines | Vasculitis |
Gold compounds | |
Estrogens | Thrombotic lesion induction |
Progestational agents | |
Alosetron | Increased intracolic pressure |
Danazol | |
Glycerin enema | |
Carboplatin | Undetermined |
Flutamide | |
Glutaraldehyde | |
Hyperosmotic saline laxatives | |
Interferon-α | |
Mycophenolate mofetil | |
Paclitaxel | |
Simvastatin | |
Tegaserod |
- Citation: Sherid M, Samo S, Sulaiman S, Gaziano JH. Ischemic colitis induced by the newly reformulated multicomponent weight-loss supplement Hydroxycut®. World J Gastrointest Endosc 2013; 5(4): 180-185
- URL: https://www.wjgnet.com/1948-5190/full/v5/i4/180.htm
- DOI: https://dx.doi.org/10.4253/wjge.v5.i4.180